GH1 and neoplasm: Patients with ≥1 degree of hypopituitarism from treatment for prior tumor (PA 88%, CP 12%). Patients with acromegaly or Cushing disease and those on GH replacement therapy were excluded. Deaths within 1 month of surgery were excluded.